S.BIOMEDICS
- Biotech or pharma, therapeutic R&D
S. Biomedics is a clinical-stage company based in Korea, specializing in developing stem-cell-derived therapies.
At AD/PD 2025, we announced a 1-year interim analysis of our TED-A9, ESC-derived ventral midbrain dopaminergic precursors for the treatment of Parkinson's disease, currently in a Phase 1/2a clinical study. TED-A9 has demonstrated significant improvement in patients' motor and non-motor symptoms, as measured by scales including MDS-UPDRS and Hoehn & Yahr scores.
Based on the observed therapeutic effects of TED-A9 compared to traditional therapies, we are planning to conduct further trials globally, contributing to improving the quality of life of PD patients worldwide.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}